The California stem cell agency has released additional information on its proposed, first-ever funding round for participation in clinical trials.
The plan, expected to be approved on Thursday by directors, would provide $50 million for one or two trials and would be limited to “novel cell therapies from pluripotent stem cells.” Both businesses and non-profit institutions could compete, but
